Safinamide Enhances Control of Parkinson's: Combining the drug with dopamine enhanced the latter's efficacy, which can lessen over time.

BOSTON — The combination of safinamide with ongoing dopamine agonist monotherapy lessened motor and cognitive symptoms in a group of patients with Parkinson's disease, according to the results of a randomized, placebo-controlled, multinational phase III trial. The higher dose tested offered no advantage over the lower dose, according to the presentation made by Dr. Fabrizio Stocchi at the 59th Annual Meeting of the American Academy of Neurology.